GeoVax Labs, Inc. (GOVXD.OB) Moving Forward with Leading HIV/AIDS Vaccine Candidate, Reports 1Q 2010 Financial Data
GeoVax Labs, Inc., developer of HIV/AIDS and other vaccines whose DNA and MVA vaccines showed increased anti-HIV immunological response in Phase 1 human clinical data, leading to Phase 2 testing in 09 (currently ongoing), and FDA Phase 1 therapeutic trial approval for patients infected with HIV, disclosed 3-month (ending Mar.31) financial data today. With a bright future doling out lucrative manufacturing and distribution rights to a global market eager for these revolutionary products, GOVXD ended the period with $2,603,108 in cash as net loss declined 19.8% from the same period in 09 to $690,789 – losses were offset by grants…